Infection with multiple HIV-1 founder variants is associated with lower viral replicative capacity, faster CD4+ T cell decline and increased immune activation during acute infection.
Gladys N MachariaLing YueEcco StallerDario DilerniaDaniel WilkinsHeeyah SongEdward McGowanDeborah KingPat FastNesrina ImamiMatthew A PriceEduard J SandersEric HunterJill GilmourPublished in: PLoS pathogens (2020)
HIV-1 transmission is associated with a severe bottleneck in which a limited number of variants from a pool of genetically diverse quasispecies establishes infection. The IAVI protocol C cohort of discordant couples, female sex workers, other heterosexuals and men who have sex with men (MSM) present varying risks of HIV infection, diverse HIV-1 subtypes and represent a unique opportunity to characterize transmitted/founder viruses (TF) where disease outcome is known. To identify the TF, the HIV-1 repertoire of 38 MSM participants' samples was sequenced close to transmission (median 21 days post infection, IQR 18-41) and assessment of multivariant infection done. Patient derived gag genes were cloned into an NL4.3 provirus to generate chimeric viruses which were characterized for replicative capacity (RC). Finally, an evaluation of how the TF virus predicted disease progression and modified the immune response at both acute and chronic HIV-1 infection was done. There was higher prevalence of multivariant infection compared with previously described heterosexual cohorts. A link was identified between multivariant infection and replicative capacity conferred by gag, whereby TF gag tended to be of lower replicative capacity in multivariant infection (p = 0.02) suggesting an overall lowering of fitness requirements during infection with multiple variants. Notwithstanding, multivariant infection was associated with rapid CD4+ T cell decline and perturbances in the CD4+ T cell and B cell compartments compared to single variant infection, which were reversible upon control of viremia. Strategies aimed at identifying and mitigating multivariant infection could contribute toward improving HIV-1 prognosis and this may involve strategies that tighten the stringency of the transmission bottleneck such as treatment of STI. Furthermore, the sequences and chimeric viruses help with TF based experimental vaccine immunogen design and can be used in functional assays to probe effective immune responses against TF.
Keyphrases
- men who have sex with men
- hiv testing
- hiv positive
- immune response
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- hepatitis c virus
- randomized controlled trial
- sars cov
- copy number
- quantum dots
- hiv aids
- risk assessment
- drug induced
- physical activity
- cell therapy
- body composition
- mesenchymal stem cells
- smoking cessation
- inflammatory response
- toll like receptor
- early onset
- hepatitis b virus
- bone marrow
- extracorporeal membrane oxygenation
- dendritic cells
- respiratory failure
- genome wide analysis